Global CDMO Opportunity Jubilant Pharmova operates a robust CDMO Sterile Injectables business with capabilities in sterile fill and finish, ophthalmic products, and ampoules, across regulated markets including the USA and Europe. This presents a sales opportunity to offer contract manufacturing, process development, and regulatory support services to pharma and biotech companies seeking reliable, scalable sterile manufacturing and add-on ophthalmic capabilities.

R&D and CRDMO Growth The company has active CRDMO and Drug Discovery Services with centers in Bengaluru, Noida, and France, signaling ongoing demand for research, development, and early-stage manufacturing support. This suggests cross-selling opportunities for discovery services, preclinical and translational research collaborations, and expansion of CRO/CRDMO partnerships with mid- to late-stage drug developers.

Radiopharma Network With 45 radiopharmacies in the US and a focus on Radiopharma, Jubilant offers a gateway for suppliers of radiopharmaceutical logistics, radiolabeling materials, and regulatory/compliance services, as well as potential collaboration on new radiopharmaceutical products and supply chain optimization for US customers.

Allergy and Biologics Expansion The Allergy Immunotherapy business and Jubilant Therapeutics indicate exposure to biologics and complex biologic-derived products, including antibody-drug conjugates in Europe. There are opportunities to provide specialized APIs, bioprocess development, downstream purification, analytical testing, and quality systems support to biologics manufacturers targeting allergy, oncology, and auto-immune indications.

Financial Signals and Partnerships Recent revenue growth in FY26 and strategic partnerships, notably with Pierre Fabre for biologics capabilities, highlight a momentum for collaboration on high-value therapies and international expansion. This presents a sales angle to offer bespoke manufacturing collaborations, supply chain services, and capital-efficient manufacturing solutions to support joint go-to-market initiatives and capability scaling.